FDA Grants Quick Review for Three Psychedelic Drug Trials in Major Policy Shift

The Food and Drug Administration granted expedited review status to three experimental psychedelic therapies on Friday, marking the most concrete regulatory advancement yet in the Trump administration's push to accelerate access to alternative mental health treatments.

UK-based Compass Pathways, Wisconsin's Usona Institute, and New York's Transcend Therapeutics each received priority review vouchers for drugs targeting major depressive disorder and post-traumatic stress disorder—conditions that collectively affect more than 30 million Americans and often prove resistant to conventional treatments.

Compass Pathways: Synthetic Psilocybin for Treatment-Resistant Depression

Compass Pathways announced Friday that the FDA granted its request for rolling review of an experimental synthetic psilocybin therapy specifically developed for patients whose depression hasn't responded to at least two prior antidepressant treatments. The company cited positive data from two large Phase 3 trials in its press release, though full results have not yet been published in peer-reviewed journals.

Treatment-resistant depression affects approximately 2.8 million Americans, leaving patients cycling through multiple medications with limited success and significantly elevated suicide risk. Current FDA-approved options for this population include electroconvulsive therapy, which carries cognitive side effects, and the nasal spray esketamine, which requires in-clinic administration and carries abuse potential concerns.

Psilocybin-assisted therapy, by contrast, involves one or two supervised dosing sessions combined with psychological support, with effects potentially lasting months. The Compass formulation uses a synthetic version of the compound found in so-called magic mushrooms, allowing for precise dosing and quality control impossible with naturally derived substances.

Usona Institute: Natural Psilocybin for Major Depression

Usona Institute, a Wisconsin-based nonprofit medical research organization, also received a priority review voucher for its work with psilocybin to treat major depressive disorder. Unlike Compass's synthetic approach, Usona uses naturally derived psilocybin in its research protocol.

In an email statement, a Usona spokesperson emphasized that the voucher expedites the administrative timeline without lowering scientific or regulatory standards. The organization expects the review process to last one to two months after submitting its complete application.

Usona's research has focused particularly on the therapeutic potential of guided psilocybin experiences combined with structured psychotherapy. Their Phase 2 trials demonstrated rapid, sustained reductions in depressive symptoms, with many participants reporting benefits persisting six months after a single session.

The nonprofit structure distinguishes Usona from commercial pharmaceutical development, potentially allowing for different pricing and access models if approval is granted. The organization has committed to making any approved therapy accessible regardless of insurance status or ability to pay.

Transcend Therapeutics: Methylone for PTSD

New York-based Transcend Therapeutics received a priority review voucher for methylone, an experimental compound related to MDMA but with potentially different safety and efficacy profiles, specifically for PTSD treatment.

Chief Executive Officer Blake Mandell confirmed the voucher award Friday. Methylone, sometimes known by the street name "Molly" in unregulated contexts, shares structural similarities with MDMA but produces somewhat different subjective effects and may carry reduced cardiovascular risks.

Transcend's development program targets the same PTSD population that Lykos Therapeutics attempted to serve with MDMA-assisted therapy—a drug application the FDA rejected in August 2025 despite Phase 3 data showing 67% of participants no longer met PTSD criteria after treatment. The rejection cited trial design concerns rather than efficacy questions, leaving the door open for future applications addressing methodological issues.

PTSD affects approximately 13 million Americans annually, with particularly high prevalence among military veterans, first responders, and survivors of sexual assault. Current FDA-approved treatments include sertraline and paroxetine, which show limited efficacy and high dropout rates in real-world use.

Veterans Drive Policy Momentum

The push for expanded psychedelic research and access has been led significantly by military veterans and their advocacy organizations, who point to the disparity between combat deaths and suicide deaths among former service members.

"There's a battle still raging in their mind that we don't fully understand biochemically," FDA Commissioner Marty Makary said in recent comments addressing veteran mental health. "When you see something that looks promising, you have to pursue it with rigor but also with urgency."

Veterans organizations including the Veterans of Foreign Wars and Iraq and Afghanistan Veterans of America have lobbied aggressively for accelerated approval pathways, citing the approximately 6,000 veteran suicides annually and the inadequacy of current treatment options for service-connected PTSD.

Broader Policy Context

The FDA action comes just six days after President Trump signed an executive order directing the Department of Health and Human Services to accelerate access to treatments for serious mental illness, including specific provisions for psychedelic research. The order established $50 million in funding for state-level ibogaine research and created a pathway for Schedule I rescheduling for substances completing Phase 3 trials.

It also follows a Justice Department announcement Thursday easing restrictions on state-licensed medical marijuana programs, signaling a broader administration shift toward substances historically classified as having high abuse potential and no medical value.

The three priority vouchers issued Friday represent concrete regulatory action beyond the executive order's policy directives. Priority review typically reduces FDA evaluation time from ten months to six, though the agency maintains that scientific standards remain unchanged.

Clinical and Commercial Implications

For patients with treatment-resistant conditions, the development timeline matters enormously. Even with expedited review, final FDA approval—if granted—likely remains years away. Compass Pathways has completed Phase 3 trials, putting it closest to potential approval, while Usona and Transcend appear to be earlier in the development process.

The commercial landscape for psychedelic therapies remains uncertain. Compass Pathways operates as a publicly traded company with significant venture capital backing, positioning for potential market exclusivity if approved. Usona's nonprofit model suggests different access priorities. Transcend, as a private company, has not disclosed detailed development timelines or commercialization strategies.

Insurance coverage represents another significant unknown. Current FDA-approved treatments for depression and PTSD vary widely in coverage, with esketamine often requiring prior authorization and facing reimbursement challenges. The supervised administration model required for psychedelic therapies—involving trained clinicians present throughout the experience—adds substantial cost beyond the drug itself.

Scientific and Ethical Considerations

The rapid regulatory advancement raises important questions about evidence standards for psychoactive substances. The FDA's rejection of Lykos Therapeutics' MDMA application in 2025 highlighted concerns about functional unblinding—participants and researchers often can tell whether someone received active drug or placebo based on subjective effects—and psychotherapy standardization across trial sites.

These methodological challenges are inherent to psychedelic research rather than specific to any particular compound. How the FDA applies consistent standards across different development programs while accommodating the unique characteristics of psychoactive therapies will significantly shape the field's future.

Ethical questions also persist about equitable access. The current clinical trial model for psychedelic therapies often excludes participants with certain psychiatric histories, substance use disorders, or cardiovascular conditions—precisely the populations most affected by the mental health crises these treatments aim to address.

Looking Forward

The three priority vouchers issued Friday represent the most significant federal advancement for psychedelic medicine since the 1970 Controlled Substances Act effectively halted research for decades. Whether this momentum continues depends on trial results, regulatory decisions, and the political durability of the current administration's policies.

For the millions of Americans whose depression and PTSD have resisted conventional treatment, the development offers something in short supply: hope backed by regulatory seriousness and emerging clinical evidence. The path from priority voucher to pharmacy shelf remains long and uncertain, but shorter than it appeared just weeks ago.

---

If you or someone you know is struggling with depression or PTSD, help is available. Contact the 988 Suicide & Crisis Lifeline by calling or texting 988, or visit 988lifeline.org. For treatment resources, explore our guides to mental health and addiction care and psychedelic-assisted therapy research.